Representation of Distribution Grid Expansion Costs in Power System Planning

The shift towards clean energy brings about notable transformations to the energy system. In order to optimally plan a future energy system, it is necessary to consider the influence of several sectors as well as the interaction of the transmission grid and distribution grid. The concept of Feasible Operation Region (FOR) is a detailed approach to representing the operational dependencies between the transmission and distribution grid. However, in previous planning procedures, only a simplified expansion of the distribution grids can be taken into account. With the method presented in this paper, a Feasible Planning Region (FPR) is developed, which represents the operational boundaries of the distribution grids for several expansion stages and thus represents an admissible solution space for the planning of distribution grids in systemic planning approaches. It hence enables a more detailed representation of the necessary distribution grid expansion for the integration of distributed technologies in an optimized energy system of the future. In this paper, we present the method by which the FPR is formed and its integration into an energy system planning formulation. In the results, the FPR is presented for different voltage levels, and its use in power system planning is demonstrated

Beratungsleistungen zur Verwendung praxisorientierter, marktverfügbarer Robotik in Bauvorhaben des Bau- und Liegenschaftsbetriebes NRW: Studie im Auftrag des Bau- und Liegenschaftsbetriebes Nordrhein-Westfalen

Der Bau- und Liegenschaftsbetrieb Nordrhein-Westfalen (BLB NRW) gehört zu den großen Auftraggebern von Bauleistungen am Markt und ist interessiert an Optimierungspotenzialen (u. a. hinsichtlich Zeit, Kosten, Nachhaltigkeit) bei seinen Baustellenabläufen. Der Einsatz von Baurobotern bildet hierbei eine vielversprechende Option, welche u. a. im Hinblick auf aktuelle Entwicklungsstände (TRL), Einsatzpotenziale sowie technische, logistische und regulatorische Randbedingungen eruiert werden muss. Vor diesem Hintergrund war der BLB auf der Suche nach Beratungsleistungen im genannten Themenfeld. Die vorliegende Studie legt den aktuellen Stand von Technologien, Prozessen und Maschinen dar, zeigt Entwicklungstrends auf und ordnet die Möglichkeiten und Herausforderungen bezüglich eines zeitnahen und praxistauglichen Einsatzes von Baurobotiksystemen unter Beachtung geltender Regularien ein. Der Bericht fasst die Ergebnisse der Forschungs- und Entwicklungsarbeiten der GWT-TUD GmbH (GWT) zusammen, welche stellvertretend durch die beiden Projektleiter Prof. Dr.-Ing. Frank Will (Professur für Baumaschinen) und Prof. Dr.-Ing. Jens Otto (TU Dresden, Institut für Baubetriebswesen) erarbeitet wurden. Auftraggeber der Studie war der Bau- und Liegenschaftsbetrieb des Landes Nordrhein-Westfalen

Study protocol of the German "Registry for the Detection of Late Sequelae after Radiotherapy in Childhood and Adolescence" (RiSK)

<p>Abstract</p> <p>Background</p> <p>Late effects after radiotherapy in childhood and adolescence have mainly been characterized retrospectively with small patient numbers. However, these analyses are limited due to little information regarding organ dose levels in many cases. To overcome this limitation, the German Group of Paediatric Radiation Oncology (APRO) established the „Registry for the evaluation of late side effects after radiation in childhood and adolescence” (RiSK). The study protocol and the documentation forms are given in this publication.</p> <p>Methods/Design</p> <p>Radiation parameters including detailed organ doses as well as toxicity evaluations are collected prospectively from centres all over Germany. Standardized documentation forms are used. These forms are given in an English and German version as additional files to this publication. Documentation is planned for all children who receive radiotherapy in one of the therapy trials of the "German Society of Paediatric Oncology and Haematology (GPOH)". The study started in a pilot phase in June 2001 in few centres. Since 2004 documentation has been performed all over Germany and is still on-going.</p> <p>Discussion</p> <p>To our knowledge, "RiSK" is the only multi-centre study that evaluates radiation associated side effects prospectively with detailed information about organ dose levels. With ongoing recruitment and prolongation of follow-up powerful data will be obtained in a few years. A broad use and international cooperation are welcome.</p

"What's (the) Matter?", A Show on Elementary Particle Physics with 28 Demonstration Experiments

We present the screenplay of a physics show on particle physics, by the Physikshow of Bonn University. The show is addressed at non-physicists aged 14+ and communicates basic concepts of elementary particle physics including the discovery of the Higgs boson in an entertaining fashion. It is also demonstrates a successful outreach activity heavily relying on the university physics students. This paper is addressed at anybody interested in particle physics and/or show physics. This paper is also addressed at fellow physicists working in outreach, maybe the experiments and our choice of simple explanations will be helpful. Furthermore, we are very interested in related activities elsewhere, in particular also demonstration experiments relevant to particle physics, as often little of this work is published. Our show involves 28 live demonstration experiments. These are presented in an extensive appendix, including photos and technical details. The show is set up as a quest, where 2 students from Bonn with the aid of a caretaker travel back in time to understand the fundamental nature of matter. They visit Rutherford and Geiger in Manchester around 1911, who recount their famous experiment on the nucleus and show how particle detectors work. They travel forward in time to meet Lawrence at Berkeley around 1950, teaching them about the how and why of accelerators. Next, they visit Wu at DESY, Hamburg, around 1980, who explains the strong force. They end up in the LHC tunnel at CERN, Geneva, Switzerland in 2012. Two experimentalists tell them about colliders and our heroes watch live as the Higgs boson is produced and decays. The show was presented in English at Oxford University and University College London, as well as Padua University and ICTP Trieste. It was 1st performed in German at the Deutsche Museum, Bonn (5/'14). The show has eleven speaking parts and involves in total 20 people.Comment: 113 pages, 88 figures. An up to date version of the paper with high resolution pictures can be found at http://www.th.physik.uni-bonn.de/People/dreiner/Downloads/. In v2 the acknowledgements and a citation are correcte

Tenosynovial giant cell tumors as accidental findings after episodes of distortion of the ankle: two case reports

<p>Abstract</p> <p>Introduction</p> <p>Tenosynovial giant cell tumors are benign tumors of uncertain pathogenesis. They occur in the joints, tendons and synovial bursas. Due to a high recurrence rate of up to 50%, some authors call a giant cell tumor a semimalignant tumor. To date, less than 10 cases of tenosynovial giant cell tumor of the ankle have been published in the international medical literature.</p> <p>Case presentation</p> <p>In this case report, we present two patients with localized tumors that were detected accidentally after the occurrence of ankle sprains with persisting pain in the joint. The tumors were resected by open marginal surgery and regular follow-up examinations were carried out.</p> <p>Conclusions</p> <p>We present an unusual occurrence of a tumor along with a possible follow-up strategy, which has not been previously discussed in the international literature.</p

Kadınlar arasında

Safvet Nezihi'nin Resimli Roman Mecmuası'nda tefrika edilen Kadınlar Arasında adlı roman

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies

PURPOSE: To evaluate the clinical impact of isolated spread of medulloblastoma cells into cerebrospinal fluid without additional macroscopic metastases (M1-only). METHODS: The HIT-MED database was searched for pediatric patients with M1-only medulloblastoma diagnosed from 2000 to 2019. Corresponding clinical and molecular data was evaluated. Treatment was stratified by age and changed over time for older patients. RESULTS: 70 patients with centrally reviewed M1-only disease were identified. Clinical data was available for all and molecular data for 45/70 cases. 91% were non-WNT/non-SHH medulloblastoma (Grp3/4). 5-year PFS for 52 patients ≥ 4 years was 59.4 (± 7.1) %, receiving either upfront craniospinal irradiation (CSI) or SKK-sandwich chemotherapy (CT). Outcomes did not differ between these strategies (5-year PFS: CSI 61.7 ± 9.9%, SKK-CT 56.7 ± 6.1%). For patients < 4 years (n = 18), 5-year PFS was 50.0 (± 13.2) %. M1-persistence occurred exclusively using postoperative CT and was a strong negative predictive factor (p$_{PFS/OS}$ < 0.01). Patients with additional clinical or molecular high-risk (HR) characteristics had worse outcomes (5-year PFS 42.7 ± 10.6% vs. 64.0 ± 7.0%, p = 0.03). In n = 22 patients ≥ 4 years with full molecular information and without additional HR characteristics, risk classification by molecular subtyping had an effect on 5-year PFS (HR 16.7 ± 15.2%, SR 77.8 ± 13.9%; p = 0.01). CONCLUSIONS: Our results confirm that M1-only is a high-risk condition, and further underline the importance of CSF staging. Specific risk stratification of affected patients needs attention in future discussions for trials and treatment recommendations. Future patients without contraindications may benefit from upfront CSI by sparing risks related to higher cumulative CT applied in sandwich regimen

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies

PURPOSE: To evaluate the clinical impact of isolated spread of medulloblastoma cells into cerebrospinal fluid without additional macroscopic metastases (M1-only). METHODS: The HIT-MED database was searched for pediatric patients with M1-only medulloblastoma diagnosed from 2000 to 2019. Corresponding clinical and molecular data was evaluated. Treatment was stratified by age and changed over time for older patients. RESULTS: 70 patients with centrally reviewed M1-only disease were identified. Clinical data was available for all and molecular data for 45/70 cases. 91% were non-WNT/non-SHH medulloblastoma (Grp3/4). 5-year PFS for 52 patients ≥ 4 years was 59.4 (± 7.1) %, receiving either upfront craniospinal irradiation (CSI) or SKK-sandwich chemotherapy (CT). Outcomes did not differ between these strategies (5-year PFS: CSI 61.7 ± 9.9%, SKK-CT 56.7 ± 6.1%). For patients < 4 years (n = 18), 5-year PFS was 50.0 (± 13.2) %. M1-persistence occurred exclusively using postoperative CT and was a strong negative predictive factor (p(PFS/OS) < 0.01). Patients with additional clinical or molecular high-risk (HR) characteristics had worse outcomes (5-year PFS 42.7 ± 10.6% vs. 64.0 ± 7.0%, p = 0.03). In n = 22 patients ≥ 4 years with full molecular information and without additional HR characteristics, risk classification by molecular subtyping had an effect on 5-year PFS (HR 16.7 ± 15.2%, SR 77.8 ± 13.9%; p = 0.01). CONCLUSIONS: Our results confirm that M1-only is a high-risk condition, and further underline the importance of CSF staging. Specific risk stratification of affected patients needs attention in future discussions for trials and treatment recommendations. Future patients without contraindications may benefit from upfront CSI by sparing risks related to higher cumulative CT applied in sandwich regimen. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-021-03913-5

Sakıb

Hamiyyet'te tefrika edilen Sakıb adlı romanTefrikada yazarın adı belirtilmemiştir

Acute Muscular Sarcocystosis: An International Investigation Among Ill Travelers Returning From Tioman Island, Malaysia, 2011-2012

A large outbreak of acute muscular sarcocystosis (AMS) among international tourists who visited Tioman Island, Malaysia, is described. Clinicians evaluating travelers returning ill from Malaysia with myalgia, with or without fever, should consider AMS in their differential diagnosi